EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, AVEO Pharmaceuticals's enterprise value is $482.73 Mil.
AVEO Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Sep. 2022 was $94.32 Mil. Therefore, AVEO Pharmaceuticals's EV-to-Revenue for today is 5.12.
The historical rank and industry rank for AVEO Pharmaceuticals's EV-to-Revenue or its related term are showing as below:
AVEO'
s EV-to-Revenue Range Over the Past 10 Years
Min: -12.2 Med: 6.95 Max: 99.72
Current: 5.12
During the past 13 years, the highest EV-to-Revenue of AVEO Pharmaceuticals was 99.72. The lowest was -12.20. And the median was 6.95.
AVEO's EV-to-Revenue is not ranked
in the Biotechnology industry.
Industry Median: 7.63
vs AVEO: 5.12
AVEO Pharmaceuticals EV-to-Revenue Historical Data
The historical data trend for AVEO Pharmaceuticals's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of AVEO Pharmaceuticals's EV-to-Revenue
For the Biotechnology subindustry, AVEO Pharmaceuticals's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AVEO Pharmaceuticals's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AVEO Pharmaceuticals's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where AVEO Pharmaceuticals's EV-to-Revenue falls into.
AVEO Pharmaceuticals's current Enterprise Value is $482.73 Mil.
AVEO Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $94.32 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AVEO Pharmaceuticals's share price for today is $15.00.
AVEO Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.73.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AVEO Pharmaceuticals EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of AVEO Pharmaceuticals's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
AVEO Pharmaceuticals (AVEO Pharmaceuticals) Business Description
AVEO Pharmaceuticals Inc is a commercial-stage, oncology-focused biopharmaceutical company engaged in offering medicines that provide a better life for patients with cancer. The company markets FOTIVDA (tivozanib) in the United States. FOTIVDA is an oral, next-generation vascular endothelial growth factor receptor, or VEGFR, tyrosine kinase inhibitor, or TKI. The group primarily operates in the U.S.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AVEO has been successfully added to your 